Evidence map›Paper›PMID 36212523›Full record

ArticleAdvanced therapeutics2022

Inhaled Gold Nano-star Carriers for Targeted Delivery of Triple Suicide Gene Therapy and Therapeutic MicroRNAs to Lung Metastases: Development and Validation in a Small Animal Model.

Yi Liu, Uday Kumar Sukumar, Natacha Jugniot, Sumanth Mosale Seetharam, Adith Rengaramachandran, Negar Sadeghipour, Pinaki Mukherjee, Anandi Krishnan, Tarik F Massoud, Ramasamy Paulmurugan

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Advancements inMolecules (Basel, Switzerland) · 2024
    Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yi LiuMolecular Imaging Program at Stanford, Department of Radiology, School of Medicine, Stanford University, CA.
Uday Kumar SukumarMolecular Imaging Program at Stanford, Department of Radiology, School of Medicine, Stanford University, CA.
Natacha JugniotMolecular Imaging Program at Stanford, Department of Radiology, School of Medicine, Stanford University, CA.
Sumanth Mosale SeetharamDepartment of Pathology, School of Medicine, Stanford University, CA.
Adith RengaramachandranMolecular Imaging Program at Stanford, Department of Radiology, School of Medicine, Stanford University, CA.
Negar SadeghipourMolecular Imaging Program at Stanford, Department of Radiology, School of Medicine, Stanford University, CA.
Pinaki MukherjeeStanford Nano Shared Facility, Stanford University, CA.
Anandi KrishnanDepartment of Pathology, School of Medicine, Stanford University, CA.
Tarik F MassoudMolecular Imaging Program at Stanford, Department of Radiology, School of Medicine, Stanford University, CA.
Ramasamy PaulmuruganMolecular Imaging Program at Stanford, Department of Radiology, School of Medicine, Stanford University, CA.
Stanford Medicine · US

Funding

Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI Vittorio Sebastiano · 2007 to 2026
$71.4M
Therapeutic miRNA Modulation of Hepatocellular Carcinoma Using Ultrasound Guided Drug DeliveryR01CA209888 · NCI · STANFORD UNIVERSITY · PI DAHL, JEREMY, PAULMURUGAN, RAMASAMY · 2017 to 2021
$3.1M
Integrated Clinical and Transcriptomic Profiling to Characterize Disease PhenotypeK08HG010061 · NHGRI · STANFORD UNIVERSITY · PI KRISHNAN, ANANDI · 2018 to 2022
$955k
3D Passive Cavitation Imaging-Guided Therapeutic Delivery of MicroRNA into CancerR21EB022298 · NIBIB · STANFORD UNIVERSITY · PI PAULMURUGAN, RAMASAMY · 2016 to 2017
$441k
Celigo S Imaging Cytometer (200-BFFL-S)S10OD023518 · OD · STANFORD UNIVERSITY · PI PAULMURUGAN, RAMASAMY · 2018 to 2018
$174k
NCI NIH HHS P30 CA124435NCI NIH HHS R01 CA209888NHGRI NIH HHS K08 HG010061NIBIB NIH HHS R21 EB022298NIH HHS S10 OD023518
6 · The paper itself

Abstract

Pulmonary metastases pose significant treatment challenges for many cancers, including triple-negative breast cancer (TNBC). We developed and tested a novel suicide gene and therapeutic microRNAs (miRs) combination therapy against lung metastases

Indexed as

Genetic therapyLung neoplasmsmultiple primariesNeoplasms

Identifiers

PMID36212523
PMCPMC9543365
OpenAlexW4283024564

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.